These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7762251)

  • 21. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
    Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
    Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.
    Klumpp TR; Mangan KF; Glenn LD; Macdonald JS
    Bone Marrow Transplant; 1993 Apr; 11(4):337-9. PubMed ID: 8097937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
    van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
    Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
    Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
    Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma.
    Fermand JP; Chevret S; Hennequin C; Levy Y; Gerota J; Benbunan M; Seligmann M; Brouet JC
    Nouv Rev Fr Hematol (1978); 1991; 33(6):525-8. PubMed ID: 1687831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Gastineau DA; Tefferi A; Chen MG; Witzig TE; Greipp PR; Litzow MR
    Bone Marrow Transplant; 2000 Jul; 26(1):45-50. PubMed ID: 10918404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.
    Meehan KR; Verma UN; Cahill R; Frankel S; Areman EM; Sacher RA; Foelber R; Rajagopal C; Gehan EA; Lippman ME; Mazumder A
    Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Autologous transplantation of peripheral stem cells in treatment of recurrent multiple myeloma].
    Krejcí M; Adam Z; Mayer J; Hájek R; Vorlícek J
    Vnitr Lek; 1998 Dec; 44(12):698-701. PubMed ID: 10422512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hematopoietic stem cell transplantation in multiple myeloma].
    Vela-Ojeda J; Ruiz-Esparza MA
    Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemopoietic stem cell transplants for multiple myeloma.
    Jagannath S; Vesole DH; Tricot G; Crowley J; Salmon SE; Barlogie B
    Oncology (Williston Park); 1994 Nov; 8(11):89-103; discussion 103-6. PubMed ID: 7826841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.
    Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W
    Anticancer Res; 1998; 18(3C):2237-41. PubMed ID: 9703793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.